Planet Fitness, Inc.

Novo Nordisk A/S

Eli Lilly and Company

The hype around GLP-1-class weight loss drugs is opening up new growth opportunities for fitness club chain Planet Fitness, investment bank Stifel predicts. "We believe GLP-1 users could significantly increase fitness club subscriptions in the coming years," analyst Chris O'Call wrote in a note to clients <a href="https://www.cnbc.com/2026/01/16/this-gym-stock-could-see-a-boost-from-increase-weight-loss-pill-use-says-stifel.html">quoted</a> by CNBC. He reiterated a buy recommendation on Planet Fitness shares and a $130 target, up 31% from the Jan. 15 close.

Stifel expects fitness chain's stock to rise 30%. How will a diet pill help them? 

Sanofi

The corporation is diversifying its sources of growth beyond its key asthma drug Dupixent

Sanofi is expanding its vaccine business. It will buy Dynavax for $2.2 billion

They are different from the already-hit Wegovy and Zepbound

Lilly and Novo simultaneously filed applications for approval of new obesity drugs

Medline Inc.

Analysts saw this placement as a signal for the market

Medline shares soared 41% after this year's biggest IPO. Should you buy them?

The company has raised over $6 billion through its listing and has a valuation of over $50 billion

Biggest IPO of the year: shares of medical products giant Medline become available

Company's experimental multiple sclerosis drug fails to meet key goal in clinical trial

Sanofi's stock is down. Its sclerosis drug suffers 'double blow'

Lumexa

The company goes public on the Nasdaq under the ticker LMRI

Lumexa IPO: trading in securities of the network of diagnostic imaging centers has started 

Moderna, Inc.

Novavax, Inc.

Pfizer Inc.

The U.S. Food and Drug Administration has threatened to tighten its vaccine approval process

Moderna and Novavax shares fall amid reports of 10 likely deaths after vaccination

Merck & Co., Inc.

Regeneron Pharmaceuticals, Inc.

Increased volatility and doubts about AI's prospects have pushed the market toward defensive stocks

Healthcare has become a safe haven for investors: the sector grew by 10% in November


The White House also secured reductions in the cost of Wegovy and Pfizer's cancer drug

Novo will cut the price of Ozempic by 71% for older Americans. This will hinder revenue growth

UnitedHealth Group Incorporated

Brookfield Renewable Corporation

Norfolk Southern Corporation

They are shifting their focus to health care, manufacturing and materials, which benefit from structural changes in the economy

AI stocks have come under pressure. Which sectors are now favored by managers?

Vertex Pharmaceuticals Incorporated

Techno-billionaires from Silicon Valley are actively <a href="https://oninvest.com/article/magnaty-kremnievoj-doliny-delaut-stavki-na-omolozenie-mozno-li-na-etom-zarabotat">investing</a> in finding new ways to extend life. However, they are not only concerned about this - in San Francisco, with the support of OpenAI CEO Sam Altman and Coinbase CEO Brian Armstrong, a startup called Preventive has been secretly <a href="https://www.wsj.com/tech/biotech/genetically-engineered-babies-tech-billionaires-6779efc8">working</a> <a href="https://www.preventive.bio/blog/announcing-preventive">for</a> six months to create genetically "improved" babies using the latest DNA editing technologies. And he's not the only one. The idea is a noble one - to rid people of genetic diseases, but critics fear both failure and success of this venture.

Medicine